Form 8-K Mersana Therapeutics, For: Feb 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BTIG Upgrades Mersana (MRSN) to Buy
February 28, 2024 3:38 PM ESTBTIG analyst Kaveri Pohlman upgraded Mersana (NASDAQ: MRSN) from Neutral to Buy with a price target of $6.00.
The analyst comments "We believe that the upcoming catalysts this year could significantly de-risk the Dolasynthen platform and the lead ADC, XMT-1660 (B7-H4 Dolalock ADC),... More
